关于华厦眼科医院集团股份有限公司 部分募集资金投资项目增加实施主体的核查意见 中国国际金融股份有限公司 中国国际金融股份有限公司（以下简称"保荐机构"）作为华厦眼科医院集 团股份有限公司（以下简称"公司"）首次公开发行股票并在创业板上市的保荐 机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》等有关规定，对公司部分募投项目增加实施主体的事项进行了认真、审慎的 核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕2085 号）同意，公司首次公开发 行人民币普通股（A 股）股票 6,000.00 万股，每股发行价格为人民币 50.88 元， 募集资金总额为人民币 3,052,800,000.00 元，扣除不含税的发行费用人民币 284,307,454.70 元，实际募集资金净额为人民币 2,768,492,545.30 元。容诚会计师 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2023-023 华厦眼科医院集团股份有限公司 关于参与认购投资基金份额的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外投资概述 为促进公司未来发展，不断扩大眼科医疗网络布局，华厦眼科医院集团股份 有限公司（以下简称"公司"）与中电数字（北京）私募基金管理有限公司（以 下简称"中电数字"或"基金管理人"）、厦门市西海创业投资有限公司（以下简 称"西海创投"）、中信信托有限责任公司（以下简称"中信信托"）、厦门跃慷投 资合伙企业（有限合伙）（以下简称"跃慷投资"）共同参与投资厦门华厦聚信壹 号投资合伙企业（有限合伙）（以下简称"华厦壹号"或"基金"）并签署《厦门 华厦聚信壹号投资合伙企业（有限合伙）合伙协议》（以下简称"合伙协议"）， 其中，公司以自有资金认缴出资 8,599.50 万元作为有限合伙人。根据合伙协议， 华厦壹号将主要对眼科医院及眼科相关产业进行投资和管理，为公司的高速发展 提供优质项目储备，加速完善公司全国的眼科医疗服务网络。 根据《深圳证券交易所创业板股票上市规则》、《深圳证 ...

证券代码：301267 证券简称：华厦眼科 华厦眼科医院集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|---------------|-------------|----------------| | | | | 编号：2023-007 | | | þ特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □ | 路演活动 | | | | þ现场参观 | | | □其他 参与单位名称及人员 姓名 共计 38 名投资者参与交流，参会人员名单详见附件。 时间 2023 年 6 月 27 日 14:00-16:00 地点 上海和平眼科医院有限公司（以下简称"上海和平眼科"） 会议室 曹乃恩先生 公司董事会秘书 上市公司接待人员 郭海科先生 上海和平眼科院长 姓名 胡剑徽先生 上海和平眼科执行总经理 1、请介绍一下上海和平眼科基本情况？ 上海和平眼科医院是一家集医疗、科研、教学为一体的现 代化眼科专科医院，于 2020 年荣获"中国非公立医疗机构协 会能力评 ...

证券代码：301267 证券简称：华厦眼科 | --- | --- | --- | |--------------------|-----------------------|-------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 □ | 业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | 其他 厦门辖区上市公司 | 2023 | 参与单位名称及人员 通过全景网"投资者关系互动平台"（https://ir.p5w.net）参与 姓名 厦门辖区上市公司 2023 年投资者网上集体接待日的投资者 时间 2023 年 5 月 12 日下午 14:30-16:15 地点 "全景路演"网站（http://rs.p5w.net），或关注微信公众号：全 景财经，或下载全景路演 APP，参与本次互动交流 董事长兼总经理苏庆灿先生、财务总监陈鹭燕女士、董事会秘 上市公司接待人员 姓名 书曹乃恩先生、独立董事扈军先生 1、请问贵司有没有在广州设立分支机构的计划？ 感谢您的提问！大湾区是公司完善眼科服务网络布局的重 点区域之一，在 ...

其次，公司具备良好的品牌影响力和广泛的行业认同。华厦 眼科是全科诊疗服务体系的先行者，业务范围涵盖眼科全生命周 期，长期发展中始终坚持"医教研"一体化均衡发展。凭借尊重 临床、尊重专家、尊重知识的优秀企业文化，公司汇聚了黎晓新 教授、赵堪兴教授为代表的大批行业顶尖专家，持续打造人才培 养和诊疗技术高地，已成为一大特色，在行业内广受认可。值得 一提的是，华厦眼科紧紧把握智慧医疗发展趋势，整合优势资源， 相继推出眼科通、5G 互联网医院、全国疑难眼病会诊平台等创 新性平台，实现集团旗下医院间优质专家资源共享，更好地为集 团旗下各地医院的眼疾患者提供同质化眼科诊疗服务。 再次，华厦眼科拥有成熟的人才培养体系，有效提升医院临 床水平。公司每年都会为处于不同职业发展阶段的医生量身提供 多种多样的培训，例如集团中国眼科医师"明日之星"计划培训 体系，对各级不同层次医生，创造更多元化的职业发展选择；每 周固定举行的疑难眼病病例讨论会，让集团内所有医生有机会得 到行业巨擘面对面、零距离的带教，日积月累下来对全集团临床 诊断能力提升是显著的。 此外，公司还将在品牌影响、学科运营、技术服务及供应链 等多维度帮助旗下医院快速发展。 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2023-019 华厦眼科医院集团股份有限公司 关于参加厦门辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，华厦眼科医院集团股份有限公司（以下 简称"公司"）将参加由厦门证监局、厦门上市公司协会与深圳市全景网络有限公 司联合举办的"2023 年厦门辖区上市公司投资者集体接待日活动"，现将相关事 项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参与 本次互动交流，活动时间为 2023 年 5 月 12 日（周五） 14:30-16:15。届时公司 董事长兼总经理苏庆灿先生、财务总监陈鹭燕女士、董事会秘书曹乃恩先生以及 独立董事扈军先生将在线就公司 2022 年度业绩、公司治理、发展战略、经营状 况、融资计划和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告！ ...

Financial Performance - The company's operating revenue for Q1 2023 reached ¥930,792,120.15, representing a 15.10% increase compared to ¥808,667,287.75 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥147,199,342.42, a 21.47% increase from ¥121,180,965.35 year-on-year[4] - Basic earnings per share for Q1 2023 increased to ¥0.27, up 22.73% from ¥0.22 in the previous year[4] - The company reported a total profit of CNY 212,650,690.55 for Q1 2023, up 41.1% from CNY 150,691,797.70 in the same quarter last year[23] - Total comprehensive income for Q1 2023 reached ¥157,743,872.79, up from ¥111,299,985.87 in Q1 2022, representing an increase of approximately 41.7%[24] - Net profit attributable to the parent company was ¥150,279,161.27, compared to ¥112,139,389.14 in the same period last year, marking a growth of about 33.9%[24] Cash Flow - Cash flow from operating activities for Q1 2023 was ¥271,087,408.44, showing a significant increase of 60.24% compared to ¥169,175,858.16 in the same period last year[4] - Net cash flow from operating activities was ¥271,087,408.44, significantly higher than ¥169,175,858.16 in Q1 2022, indicating a rise of approximately 60.3%[26] - Cash inflow from investment activities totaled ¥2,813,295,828.58, compared to ¥850,083,410.21 in the previous year, showing a substantial increase of about 231.5%[26] - Net cash flow from investment activities was ¥1,361,244,349.59, a turnaround from a negative cash flow of ¥85,897,198.17 in Q1 2022[26] - Cash and cash equivalents at the end of the period reached ¥2,940,102,692.11, up from ¥1,008,902,230.19 at the end of Q1 2022, representing an increase of approximately 191.5%[27] - Total cash inflow from operating activities was ¥859,575,034.62, slightly down from ¥888,620,847.48 in the previous year[25] - Total cash outflow from operating activities decreased to ¥588,487,626.18 from ¥719,444,989.32, reflecting a reduction of about 18.2%[26] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥6,885,167,093.64, a 4.57% increase from ¥6,584,482,315.79 at the end of the previous year[4] - The company's cash and cash equivalents at the end of Q1 2023 were ¥294,795,220, reflecting a 119.17% increase from the beginning of the period[9] - Accounts receivable increased to CNY 252,028,887.45 from CNY 195,449,513.17, reflecting a growth in sales or services rendered[17] - The total current assets rose to CNY 4,886,469,752.37, compared to CNY 4,616,865,732.86 at the beginning of the year, showing a positive trend in asset management[17] - Non-current assets totaled CNY 1,998,697,341.27, up from CNY 1,967,616,582.93, indicating ongoing investments in long-term assets[18] - The company's total liabilities increased, with accounts payable rising to CNY 291,734,065.74 from CNY 208,301,944.41, suggesting higher operational costs or increased purchasing activity[18] - Total liabilities rose to CNY 1,601,535,922.80, compared to CNY 1,456,588,992.67 in the previous year, marking an increase of 9.9%[20] - The total equity attributable to shareholders of the parent company increased to CNY 5,259,515,606.64, up from CNY 5,114,136,775.46, reflecting a growth of 2.8%[20] Research and Development - Research and development expenses for Q1 2023 amounted to ¥15,018,600, representing a 92.57% increase year-on-year, indicating a focus on clinical research[9] - Research and development expenses increased significantly to CNY 15,018,634.57, up 92.5% from CNY 7,798,926.88 in Q1 2022[22] Market Strategy - The company is focusing on expanding its market presence and enhancing its service offerings, although specific new products or technologies were not detailed in the report[16] - The company plans to continue expanding its market presence and investing in new technologies to enhance service offerings[1] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,926, indicating a stable shareholder base[10] - The report indicates that the actual controller, Su Qingcan, holds a total of 352,796,200 shares, representing 63.00% of the company's total shares, reflecting strong insider confidence[14] Audit Information - The company did not undergo an audit for the Q1 2023 report[28]

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 2.8 yuan per 10 shares (including tax) based on a base of 560,000,000 shares[5]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% compared to the previous year[18]. - The company achieved operating revenue of 3.233 billion yuan, a year-on-year increase of 5.51%, and a net profit attributable to shareholders of 512 million yuan, up 12.50% compared to the same period last year[87]. - The gross profit margin for the year was reported at 60%, maintaining a stable level compared to 2021[23]. - The company aims to achieve a net profit of RMB 300 million in 2023, with a growth target of 20%[23]. - The net profit attributable to shareholders for 2022 was ¥511,793,450.73, which is a 12.50% increase from ¥454,919,067.88 in 2021[5]. - The company’s operating revenue for 2022 was ¥3,233,246,188.16, representing a 5.51% increase compared to ¥3,064,436,598.39 in 2021[5]. - The company reported a net cash flow from operating activities of ¥769,983,013.73, down 3.51% from ¥798,017,131.02 in 2021[5]. Market Expansion and Strategy - The company is expanding its market presence by opening 10 new clinics in key cities across China in the upcoming year[19]. - The company plans to enhance its digital services, aiming for a 30% increase in online consultations by the end of next year[19]. - The company is investing 50 million RMB in research and development for innovative eye treatment solutions[18]. - The company has established partnerships with local healthcare providers to improve service delivery and patient access[23]. - The company aims to increase the proportion of revenue from consumer medical services by focusing on non-insured projects such as refractive surgery and dry eye treatment[180]. - The company will adopt a dual approach of "self-built + acquisitions" to accelerate market expansion and strengthen its competitive position[180]. - The company plans to enhance its medical service capabilities by introducing advanced equipment and technologies to meet the diverse needs of the ophthalmology market[181]. Risk Management - The company emphasizes the importance of risk awareness regarding future development plans and operational strategies, highlighting potential risks and countermeasures[4]. - The company has not identified any major risk factors that could severely impact its operational and financial status or profitability[4]. - The company acknowledges the management risks associated with rapid expansion and is focused on refining its operational management system to ensure effective oversight of new facilities[195]. - The company is aware of the potential medical risks inherent in treatment procedures and is committed to maintaining high standards of care to mitigate these risks[198]. Research and Development - The company is investing 50 million RMB in research and development for innovative eye treatment solutions[18]. - The company has obtained a total of 87 patent authorizations and registered 161 software copyrights as of the end of the reporting period[70]. - The company published a total of 126 academic papers during the reporting period, with 55 included in SCI[71]. - The company is actively developing an AI-assisted screening algorithm for age-related macular degeneration (AMD), aiming for a sensitivity of at least 90% and specificity of at least 95%[115]. - The company is focusing on the development of new technologies and products to improve patient outcomes and satisfaction[140]. Operational Efficiency - Operational efficiency improvements led to a reduction in costs by 5%, enhancing overall profitability[19]. - The company has implemented a comprehensive medical quality control system, continuously improving service quality through regular training and supervision, ensuring standardized clinical practices[80]. - The company has a centralized procurement strategy to enhance bargaining power and ensure high-quality supplies, with a strict supplier selection process[59]. Community Engagement and Social Responsibility - In 2022, the company provided public welfare treatment for over 30,000 eye disease patients and distributed more than 18,000 pairs of glasses, contributing to the "Healthy China" initiative[82]. - The "Angel Bright Eyes" program has served nearly 10 million children and adolescents, establishing refractive development records for over 300,000 students and providing over 50,000 pairs of glasses[84]. - The company conducted 2,750 eye health screening events, reaching 5.05 million students in 2022, actively participating in myopia prevention efforts[83]. Talent Development - The company has established partnerships with universities such as Xiamen University and Peking University for talent training and clinical research[72]. - The company has launched the "China Ophthalmologist Tomorrow Star Program" to cultivate clinical and research talents in ophthalmology, with over 300 graduates and more than 60,000 surgeries performed[76]. - The company recognizes the risk of talent scarcity in the ophthalmology field and is committed to optimizing talent attraction, training, and incentive mechanisms to maintain a stable and high-quality medical workforce[197]. Investor Relations - The company engaged in discussions regarding its operational performance and future development strategies with institutional investors[200]. - The discussions took place in December 2022, suggesting a strategic timing for investor relations[200]. - The company emphasized its growth strategies and market expansion plans during the meetings[200].

证券代码：301267 证券简称：华厦眼科 公告编号：2023-017 出席本次业绩说明会的人员有：公司董事长兼总经理苏庆灿先生、财务总监 陈鹭燕女士、董事会秘书曹乃恩先生以及独立董事扈军先生、保荐代表人赵冀先 生。 为提升公司与投资者之间的交流效率，公司欢迎广大投资者于 2023 年 5 月 3 日（星期三）17:00 前，将您关注的问题通过下方二维码进行提交或通过电子 邮件的形式发送至公司电子邮箱：zhengquanbu@huaxiaeye.com，公司将在本次 说明会上对投资者普遍关注的问题进行回答。欢迎广大投资者积极参与！ 华厦眼科医院集团股份有限公司 关于举行 2022 年度业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）《2022 年年度报告》 及其摘要于 2023 年 4 月 24 日在中国证监会指定的创业板信息披露网站巨潮资讯 网（http://www.cninfo.com.cn）上披露。 为便于广大投资者进一步了解公司的经营业绩、财务状况等情况，公司定于 2023 年 5 月 ...